The existing authors executed an open-label pilot review that administered psilocybin to fifteen cure-resistant tobacco/nicotine-dependent people who smoke, within the context of cognitive behavioral therapy for cigarette smoking cessation [fifty eight]. Individuals have been administered ~0.29 mg/kg oral psilocybin to the participant’s focus on